Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 13/20 | 0.71 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14162953 | 1.00 | NFE2L2 (0.71) | NFE2L2RELANPC1PKMNFKB1 | |
| SCHEMBL3434176 | 1.00 | NFE2L2 (0.71) | NFE2L2RELANPC1PKMNFKB1 | |
| SCHEMBL2234105 | 0.84 | NFE2L2 (1.00) | NFE2L2RELANPC1PKMNFKB1 | |
| SCHEMBL9419281 | 0.81 | NFE2L2 (0.46) | NFE2L2RELA | |
| SCHEMBL9419282 | 0.81 | NFE2L2 (0.46) | NFE2L2RELA | |
| SCHEMBL17371178 | 0.81 | NFE2L2 (0.46) | NFE2L2RELA | |
| SCHEMBL333121 | 0.81 | NFE2L2 (0.41) | NFE2L2 | |
| SCHEMBL17591558 | 0.81 | NFE2L2 (0.41) | NFE2L2 | |
| SCHEMBL30335453 | 0.81 | NFE2L2 (0.41) | NFE2L2 | |
| SCHEMBL333122 | 0.81 | NFE2L2 (0.41) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-2970112-B1 | PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-03-12 | — | — | EP | disclosed |
| EP-2968210-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY | BIO PHARM SOLUTIONS CO LTD (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-111419830-B | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes | 比皮艾思药物研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996905-A | Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases | 生物药品解决方案有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-109939092-B | Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome | 比皮艾思药物研发有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109071424-B | Sulfamate derivative compound, preparation method and application thereof | 生物药品解决方案有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-101041648-B | Inverse type-1,2-cyclopropane derivative and preparation method thereof | UNIV SHANGHAI | 2010-08-18 | — | — | CN | disclosed |
| CN-101768129-A | Production intermediate of isoxazoline-substituted benzamide compound | NISSAN CHEMICAL IND LTD | 2010-07-07 | — | — | CN | disclosed |
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-09 | — | — | US | disclosed |
| CN-101041648-A | Inverse type-1,2-cyclopropane derivative and preparation method thereof | UNIV SHANGHAI (CN) | 2007-09-26 | — | — | CN | disclosed |
| CN-1930136-A | isoxazoline-substituted benzamide compound and pest control agent | NISSAN CHEMICAL IND LTD | 2007-03-14 | — | — | CN | disclosed |
| US-6372911-B1 | REACTING COMPOUND CONTAINING AT LEAST ONE CARBON-CARBON DOUBLE BOND WITH CARBAMATE IN AQUEOUS SOLVENT IN PRESENCE OF BASE, OSMIUM CATALYST, CO-OXIDANT, AND OPTIONALLY ASYMMETRIC LIGAND, TO FORM REACTION MIXTURE CONTAINING BETA-HYDROXY CARBAMATE | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
| EP-0350069-B1 | METHOD FOR OXIDIZING UNSATURATED AROMATIC COMPOUNDS | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-4967009-A | REACTING UNSATURATED AROMATIC COMPOUNDS WITH AROMATIC IODOSYL COMPOUNDS TO YIELD AROMATIC ALDEHYDES OR KETONES | NIPPON PETROCHEMICALS CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0350069-A2 | Method for oxidizing unsaturated aromatic compounds | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4140514-A | HERBICIDES | CHEVRON RESEARCH COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | NFE2L2 4207/4885RELA 3330/4885NPC1 2207/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | NFE2L2 537/4885RELA 322/4885NPC1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.